Treatment of malignant melanoma at the stage of distant metastasis;Therapie des malignen melanoms im stadium der fernmetastasierung

Hautarzt

Volumn 55, Issue 2, 2004, Pages 195-213

  Garbe, C ^a   Eigentler, T K ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Chemoimmunotherapy; Chemotherapy; Distant metastasis; Melanoma; Surgery

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BLEOMYCIN; CARMUSTINE; CISPLATIN; DACARBAZINE; DIPYRONE; FOTEMUSTINE; FUROSEMIDE; HYDROXYUREA; INTERLEUKIN 2; LOMUSTINE; PARACETAMOL; TAMOXIFEN; TEMOZOLOMIDE; VINCRISTINE; VINDESINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; NITROSOUREA DERIVATIVE; ORGANOPHOSPHORUS COMPOUND;

BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; DEPRESSION; HUMAN; LIVER TOXICITY; MELANOMA; METASTASIS; NEUROTOXICITY; PALLIATIVE THERAPY; REVIEW; TREATMENT INDICATION; BONE TUMOR; BRAIN TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; IMMUNOTHERAPY; LIVER TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; MORTALITY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RADIATION DOSE; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SKIN TUMOR; TIME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DACARBAZINE; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM METASTASIS; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PALLIATIVE CARE; PROGNOSIS; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIALS; SKIN NEOPLASMS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; VINDESINE;

EID: 1642366280     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-003-0684-1     Document Type: Review

References (51)

1. Atkins MB, Lotze MT, Dutcher JP et al. (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116
2. Atzpodien J, Neuber K, Kamanabrou D et al. (2002) Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer 86:179-184
3. Bajetta E, Di Leo A, Zampino MG et al. (1994) Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 12:806-811
4. Bleehen NM, Newlands ES, Lee SM et al. (1995) Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13:910-913
5. Brega K, Robinson WA, Winston K, Wittenberg W (1990) Surgical treatment of brain metastases in malignant melanoma. Cancer 66:2105-2110
6. Buchsbaum JC, Suh JH, Lee SY et al. (2002) Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer 94:2265-2272
7. Carmichael J, Atkinson RJ, Calman KC et al. (1982) A multicentre phase II trial of vindesine in malignant melanoma. Eur J Cancer Clin Oncol 18:1293-1295
8. Carter RD, Krementz ET, Hill GJ et al. (1976) DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065). Cancer Treat Rep 60:601-609
9. Chapman PB, Einhorn LH, Meyers ML et al. (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745-2751
10. Chiarion-Sileni V, Nortilli R, Aversa SM et al. (2001) Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res 11:189-196
11. Cocconi G, Bella M, Calabresi F et al. (1992) Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 327:516-523
12. Costanzi JJ, Al-Sarraf M, Groppe C et al. (1982) Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group Study. Med Pediatr Oncol 10:251-258
13. Creagan ET, Suman VJ, Dalton RJ et al. (1999) Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol 17:1884-1890
14. Dorval T, Negrier S, Chevreau C et al. (1999) Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study. Cancer 85:1060-1066
15. Douglas JG, Margolin K (2002) The treatment of brain metastases from malignant melanoma. Semin Oncol 29:518-524
16. Eigentler TK, Caroli UM, Radny P, Garbe C (2003) Palliative therapy of disseminated malignant melanoma. A systematic review of 41 randomised clinical trials. Lancet Oncol 4:748-759
17. Eton O, Legha SS, Bedikian AY et al. (2002) Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20:2045-2052
18. Falkson CI, Ibrahim J, Kirkwood JM et al. (1998) Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 16:1743-1751
19. Göhl J, Meyer T, Haas C et al. (1996) Ist die chirurgische Therapie von Fernmetastasen maligner Melanome sinnvoll? Langenbecks Arch Chir Suppl Kongressbd 113:122-126
20. Gundersen S (1987) Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study. Cancer Treat Rep 71:997-999
21. Jacquillat C, Khayat D, Banzet P et al. (1990) Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66:1873-1878
22. Jansen B, Schlagbauer-Wadl H, Brown BD et al. (1998) bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4:232-234
23. John A, Tuszynski G (2001) The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7:14-23
24. Jungnelius U, Ringborg U, Aamdal S et al. (1998) Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial. Eur J Cancer 34:1368-1374
25. Kirova YM, Chen J, Rabarijaona LI et al. (1999) Radiotherapy as palliative treatment for metastatic melanoma. Melanoma Res 9:611-613
26. Kumar CC, Armstrong L, Yin Z et al. (2000) Targeting integrins alpha v beta 3 and alpha v beta 5 for blocking tumor-induced angiogenesis. Adv Exp Med Biol 476:169-180
27. Legha SS, Ring S, Bedikian A et al. (1996) Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 7:827-835
28. Legha SS, Ring S, Eton O et al. (1998) Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16:1752-1759
29. Lens MB, Dawes M (2002) Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Onco 20:1818-1825
30. Leo F, Cagini L, Rocmans P et al. (2000) Lung metastases from melanoma: when is surgical treatment warranted? Br J Cancer 83:569-572
31. McClay EF, Mastrangelo MJ, Bellet RE, Berd D (1987) Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 71:465-469
32. Middleton MR, Grob JJ, Aaronson N et al. (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158-166
33. Miller RL, Steis RG, Clark JW et al. (1989) Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. Cancer Res. 49:1871-1876
34. Mornex F, Thomas L, Mohr P et al. (2003) A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 13:97-103
35. Nelimark RA, Peterson BA, Vosika GJ, Conroy JA (1983) Vindesine for metastatic malignant melanoma. A phase II trial. Am J Clin Oncol 6:561-564
36. Parmiani G, Castelli C, Dalerba P et al. (2002) Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 94:805-818
37. Pectasides D, Yianniotis H, Alevizakos N et al. (1989) Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin. Br J Cancer 60:627-629
38. Pritchard KI, Quirt IC, Cowan DH et al. (1980) DTIC therapy in metastatic malignant melanoma: a simplified dose schedule. Cancer Treat Rep 64:1123-1126
39. Rate WR, Solin LJ, Turrisi AT (1988) Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int J Radiat Oncol Biol Phys 15:859-864
40. Retsas S, Newton KA, Westbury G (1979) Vindesine as a single agent in the treatment of advanced malignant melanoma. Cancer Chemother Pharmacol 2:257-260
41. Ridolfi R, Chiarion-Sileni V, Guida M et al. (2002) Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 20:1600-1607
42. Ringborg U, Rudenstam CM, Hansson J et al. (1989) Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study. Med Oncol Tumor Pharmacother 6:285-289
43. Robinson WA, Mughal TI, Thomas MR et al. (1986) Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. Immunobiology 172:275-282
44. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. (1999) Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17:968-975
45. Rusthoven JJ, Quirt IC, Iscoe NA et al. (1996) Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14:2083-2090
46. Seegenschmiedt MH, Keilholz L, Pieritz A et al. (1999) Locally recurrent and metastatic malignant melanoma. Long-term results and prognostic factors after percutaneous radiotherapy. Strahlenther Onkol 175:450-457
47. Seigler HF, Lucas VSJ, Pickett NJ, Huang AT (1980) DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer 46:2346-2348
48. Smith KA, Green JA, Eccles JM (1992) Interferon alpha 2a and vindesine in the treatment of advanced malignant melanoma. Eur J Cancer 28:438-441
49. Verschraegen CF, Kleeberg UR, Mulder J et al. (1988) Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A Phase II Study of the EORTC Malignant Melanoma Cooperative Group. Cancer 62:1061-1065
50. York RM, Foltz AT (1988) Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. Cancer 61:2183-2186
51. Young AM, Marsden J, Goodman A et al. (2001) Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clin Oncol (R Coll Radiol) 13:458-465